©The Author(s) 2025.
World J Transplant. Dec 18, 2025; 15(4): 105621
Published online Dec 18, 2025. doi: 10.5500/wjt.v15.i4.105621
Published online Dec 18, 2025. doi: 10.5500/wjt.v15.i4.105621
Table 1 Essential perioperative strategies in liver transplantation
| Key perioperative considerations | Core objectives | Clinical strategies | Relevance to LT outcomes |
| Anesthetic management | Optimize hemodynamic stability while minimizing cardiovascular depression | Use of balanced anesthesia with reduced myocardial depressants, individualized ventilation strategies | Reduces intraoperative cardiovascular instability and improves early graft function |
| Hemodynamic monitoring and support | Maintain adequate perfusion, prevent hypotension, and manage fluid shifts | Continuous invasive hemodynamic monitoring (arterial line, CVP), vasoactive drug titration | Prevents hemodynamic collapse, improves organ perfusion, and reduces renal dysfunction |
| Intraoperative transfusion strategies | Reduce bleeding risk, optimize coagulation, and prevent transfusion-related complications | Goal-directed transfusion strategies using viscoelastic tests (ROTEM/TEG), use of antifibrinolytics | Minimizes need for massive transfusion, reduces clotting disorders, and improves recovery |
| Metabolic and electrolyte management | Correct metabolic derangements and optimize acid-base balance | Perioperative glucose control, electrolyte replacement, correction of metabolic acidosis/ alkalosis | Prevents metabolic crises, reduces acidosis-related cardiac dysfunction, and stabilizes electrolytes |
| Surgical techniques | Enhance graft implantation, reduce ischemia-reperfusion injury, and optimize surgical technique | Use of minimally invasive techniques, normothermic regional perfusion. and/ or veno-venous bypass | Optimizes graft survival, reduces ischemic complications, and improves surgical efficiency |
| Immunosuppressive strategies | Prevent rejection while minimizing cardiovascular and metabolic toxicity | Induction therapy with IL-2 receptor antagonists, tailored CNI minimization in high-risk patients | Enhances long-term graft survival while mitigating CVD, metabolic, and renal adverse effects |
- Citation: Lulic I, Lulic D, Durekovic I, Pavicic Saric J, Bacak Kocman I, Sarec Z, Rogic D. YKL-40: Revolutionizing cardiac risk prediction and therapy in liver transplantation. World J Transplant 2025; 15(4): 105621
- URL: https://www.wjgnet.com/2220-3230/full/v15/i4/105621.htm
- DOI: https://dx.doi.org/10.5500/wjt.v15.i4.105621